The US FTC reaches settlement in post-Actavis reverse payment case (Cephalon)

The Federal Trade Commission (“FTC”) has reached a settlement resolving its claims that Cephalon, Inc. violated the antitrust laws by entering into reverse payment settlements to delay generic competition for Provigil. This is the first FTC settlement of a reverse payment case post-Actavis, and contains the largest disgorgement award in FTC history: $1.2 billion. The settlement, which was reached on the eve of trial, caps a lengthy litigation over Cephalon’s payments to four generic drug manufacturers. The Commission voted unanimously to approve the settlement, and it was filed with the court on May 28, 2015. The details of the settlement and the commissioners’ statements in support provide insight into the FTC’s approach to equitable monetary relief. The commissioners remain bitterly

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Richard G. Parker, Kenneth R. O'Rourke, Ted Hassi, Anna Fabish, The US FTC reaches settlement in post-Actavis reverse payment case (Cephalon), 28 May 2015, e-Competitions Bulletin May 2015, Art. N° 79670

Visites 51

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues